PreveCeutical Medical Inc. (“PMI”) a health and wellness company focused on utilising nature and science for the benefit of health-conscious consumers, is pleased to announce that it has signed a research and development agreement effective April 22, 2017 (the “Agreement”) with UniQuest Pty Limited (“UniQuest”) for conducting a research program (the “Research Program”) for the extraction, formulation and ex vivo evaluation of cannabinoids (CBDs) for local/direct nose-to-brain delivery via Sol-Gels. UniQuest is the main commercialisation company for The University of Queensland (“UQ”).
PMI has an interest in the preventative health sector with their lead product being derived from Caribbean Blue Scorpion Venom for the nutraceutical market. Additionally, due to increasing evidence of the clinical benefits presented by CBDs, and recent legalisation of ‘medical marijuana’ across a number of jurisdictions, PMI is seeking development and evaluation of translatable formulations for central nervous system (“CNS”) delivery of CBD’s, for which, soluble gels (sol-gels) present an ideal platform for achieving this aim, being in-solution upon administration, and rapidly gelling upon contact with mucosal tissue, paving the way for safer, reliable drug delivery for agents, such as CBDs that are rapidly metabolised, or that would benefit from direct nose-to-brain CNS delivery to provide clinical benefit.
The duration of the proposed Research Program is approximately thirty (30) months and will encompass fractionation and analysis of plant-derived CBDs, formulation of soluble-gels infused with fractionated CBD extracts, and perform CBD-fraction delivery studies from lead sol-gel formulations.
Under the Agreement, intellectual property arising from the carrying out of or results developed during the Research Program will be owned by PMI. The Agreement provides PMI with an option to negotiate with UniQuest a royalty-bearing license to use UniQuest’s intellectual property in soluble gels (sol-gels) for the commercialisation of nasal delivery of cannabinoids by PMI. UniQuest would also receive additional development-based milestone payments for the license.
“Working with UniQuest and the University of Queensland on this research program provides PMI with unique opportunities towards developing products that promote good health and wellness. Nasal delivery of CBDs will potentially provide a safer and reliable delivery platform with clinical benefits that include benefits for pain, inflammation, seizures, and mental illness”, said Stephen Van Deventer, PMI’s Chairman and Chief Executive Officer.
Information on these projects will be presented by Dr. Makarand Jawadekar, PMI’s Chief Science Officer, and Dr. Harendra (Harry) Parekh, of the University of Queensland’s School of Pharmacy, at PMI’s presentation on April 27, 2017.
The Fairmont Waterfront Hotel (900 Canada Pl, Vancouver, BC V6C 3L5), Malaspina Room
Thursday, April 27, 2017
1:30 p.m. PDT to 6:00 p.m. PDT
Confirm your attendance, register by clicking here: https://preveceutical-presentation-2017.eventbrite.ca/
Update on Previously Announced Amalgamation and Financing
The non-brokered private placement of up to 10 million units for minimum gross proceeds of at least $1 million and maximum gross proceeds of up to $5 million (the “Financing”) being conducted by Carrara Exploration Corp. (CSE:CAA) (“Carrara”), pursuant to a previously announced amalgamation agreement, is ongoing. The amalgamation agreement provides for the acquisition of PMI by Carrara by way of a three-cornered amalgamation and a reverse take-over of Carrara by PMI. A copy of the news release announcing the Financing and a copy of the amalgamation agreement were posted on Carrara’s profile on the System for Electronic Document Analysis and Retrieval (SEDAR)’s website on March 23, 2017, and can be accessed at www.sedar.com.
About UniQuest Pty Ltd.
UniQuest is the main commercialisation company of UQ, specialising in the commercialisation of intellectual property, research outcomes and expertise. UniQuest delivers commercialisation outcomes which provide impact for business, the environment, global communities and society as a whole. UniQuest benchmarks in the top 10 percent globally for university-based technology transfer. UQ innovations licenced by UniQuest are now generating annual sales of over $3 billion. For example, UQ superconductor technology, through licensing arrangements, is used in two-thirds of the world’s MRIs and more than 80 million doses of the life-saving Gardasil® cervical cancer vaccine, patented by UniQuest in 1991, have been distributed throughout 121 countries, including 72 developing countries.
One Behalf of the Board of Directors,
Stephen Van Deventer
Chairman & CEO
Disclosure: In the interest of full disclosure, we call the reader’s attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.